Madrigal Pharmaceuticals

Madrigal Pharmaceuticals

制药业

Conshohocken,Pennsylvania 48,067 位关注者

Madrigal is focused on developing therapeutics to improve the lives of patients with metabolic and fatty liver diseases.

关于我们

Madrigal (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). Our first therapy was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis. For more information, visit www.madrigalpharma.com.

网站
https://www.madrigalpharma.com/
所属行业
制药业
规模
201-500 人
总部
Conshohocken,Pennsylvania
类型
上市公司
创立
2016
领域
Liver Disease、NASH、Metabolic Disease和MASH

地点

  • 主要

    200 Barr-Harbor Dr

    Suite 200

    US,Pennsylvania,Conshohocken,19428

    获取路线

Madrigal Pharmaceuticals员工

动态

相似主页

查看职位

融资